权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Bidirectional control of Chd2 haploinsufficiency

Chd2 单倍体不足的双向控制

基本信息

批准号：
10586860
负责人：
Robert F Hunt
金额：
$ 53.72万
依托单位：
UNIVERSITY OF CALIFORNIA-IRVINE
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-01-01 至 2027-12-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10586860
关键词：
Address Adult Anatomy Area Automobile Driving Basic Science Behavior Behavioral Benchmarking Brain Brain region Cancer cell line Candidate Disease Gene Chromatin Chromatin Remodeling Factor Chromosome Mapping Clinic Clustered Regularly Interspaced Short Palindromic Repeats Communication Complex DNA Sequence Alteration Data Development Diabetes Mellitus Disease Electrophysiology (science)Embryo Engineering Epilepsy Event Exhibits Gene Expression Gene Mutation Genes Genetic Risk Genetic study Genomics Glutamates Heterozygote Hippocampus Human Immunohistochemistry In Vitro Individual Induced pluripotent stem cell derived neurons Intellectual functioning disability Laboratories Literature Longevity Malignant Neoplasms Mediating Memory Memory impairment Metformin Molecular Mus Mutation National Institute of Neurological Disorders and Stroke Neurodevelopmental Disorder Neurologic Neurons Pathologic Pathology Patients Pharmaceutical Preparations Photosensitivity Disorders Population Proliferating Pyramidal Cells Reporting Research Series Signal Transduction Stem cell transplant Structure Synapses Testing Therapeutic Translating Transplantation Western Blotting Work autism spectrum disorder behavioral study dosage hippocampal pyramidal neuron in vivo induced pluripotent stem cell loss of function mutation migration mouse genetics neurodevelopment neuronal excitability neurotransmission new therapeutic target novel novel therapeutics pharmacologic prevent stem cells synaptic function therapeutic evaluation

项目摘要

ABSTRACT Major advances have been made in mapping the genetic basis of epilepsy and other neurodevelopmental disorders (NDDs). In many cases, a candidate gene mutation has been identified, but there is no robust understanding of the neuronal causes for the particular disorder. Mutations in genes encoding chromatin regulators are commonly identified in human NDDs, with intellectual disability, autism and/or epilepsy often co- occurring in the same individual. Our recent work showed that mice with germline heterozygous mutations in Chd2 exhibit pathological changes across genomic, anatomical, electrophysiological and behavioral domains. Here, we propose studies to bidirectionally control Chd2 dosage in the developing or adult brain. Our approach involves a combination of sophisticated cellular, molecular, pharmacologic and electrophysiological approaches in conditional Chd2+/- mice and human-derived neurons. If successful, our results will provide important new information about the effects of chromatin regulators in driving NDD-associated pathologies in vivo and would provide critical proof-of-concept for the therapeutic potential of pharmacologically increasing Chd2 expression that could be rapidly translated into a new targeted therapy for Chd2 haploinsufficiency.

摘要在绘制癫痫和其他神经发育的遗传基础图方面取得了重大进展精神障碍(NDDS)。在许多情况下，已经确定了候选基因突变，但没有可靠的了解导致这种特殊疾病的神经原因。染色质编码基因的突变调节剂通常在人类NDD中被发现，并伴有智力残疾、自闭症和/或癫痫。发生在同一个人身上的。我们最近的工作表明，具有生殖系杂合突变的小鼠 CHD2表现出跨越基因组、解剖、电生理和行为领域的病理变化。在这里，我们建议研究在发育中或成人大脑中双向控制CHD2的剂量。我们的方法涉及复杂的细胞、分子、药理学和电生理学的组合条件性CHD2+/-小鼠和人源性神经元的研究方法。如果成功，我们的结果将提供关于染色质调节剂在推动新城疫相关病理中的作用的重要新信息并将为药物增加的治疗潜力提供关键的概念验证 CHD2的表达，可迅速转化为CHD2单倍体功能不全的新靶向治疗。